Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 9/20 | 0.41 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.39 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4763026 | 1.00 | CCR1 (0.44) | CCR1HTR1ALMNANPY1RNPY2R | |
| Hydrochloric Acid SCHEMBL6803575 | 0.99 | CCR1 (0.44) | CCR1HTR1ALMNANPY1RNPY2R | |
| Hydrochloric Acid SCHEMBL5584636 | 0.99 | CCR1 (0.44) | CCR1HTR1ALMNANPY1RNPY2R | |
| SCHEMBL5584254 | 0.99 | CCR1 (0.45) | CCR1HTR1ASLC6A4DRD4 | |
| SCHEMBL29723907 | 0.99 | CCR1 (0.45) | CCR1HTR1ASLC6A4DRD4 | |
| SCHEMBL5584385 | 0.99 | CCR1 (0.45) | CCR1HTR1ASLC6A4DRD4 | |
| SCHEMBL14571546 | 0.99 | CCR1 (0.45) | CCR1HTR1ASLC6A4DRD4 | |
| Hydrochloric Acid SCHEMBL5584374 | 0.95 | CCR1 (0.44) | CCR1HTR1ALMNANPY1RNPY2R | |
| Hydrochloric Acid SCHEMBL5584361 | 0.95 | CCR1 (0.44) | CCR1HTR1ALMNANPY1RNPY2R | |
| SCHEMBL6209369 | 0.95 | CCR1 (0.45) | CCR1HTR1ALMNANPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| CN-116981450-A | Combination of antidepressants and dextromethorphan for the treatment of neuropsychiatric disorders | 安泰赛普生物风投二代有限责任公司 | 2023-10-31 | — | — | CN | claimed |
| EP-3463357-B1 | (2S)-1-[4-(3,4-DICHLOROPHENYL)PIPERIDIN-L-YL]-3-[2-(5-METHYL-L,3,4-OXADIAZOL-2-YL)BENZO[B]FURAN-4-YLOXY]PROPAN-2-OL OR ITS METABOLITE FOR TREATING ANXIETY DISORDERS | MINERVA NEUROSCIENCES INC (US) | 2023-09-20 | — | — | EP | claimed |
| CN-114848641-A | Compounds or metabolites thereof for use in the treatment of anxiety disorders | 田边三菱制药株式会社 | 2022-08-05 | — | — | CN | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250228837-A1 | (2S)-1-[4-(3,4-DICHLOROPHENYL)PIPERIDIN-1-YL]-3-[2-(5-METHYL-1,3,4-OXADIAZOL-2-YL)BENZO[B]FURAN-4-YLOXY] PROPAN-2-OL OR ITS METABOLITE FOR TREATING ANXIETY DISORDERS | MINERVA NEUROSCIENCES, INC. | 2025-07-17 | — | — | US | disclosed |
| US-20250109127-A1 | METHODS OF USE OF PHENOXYPROPYLAMINE COMPOUNDS TO TREAT DEPRESSION | MINERVA NEUROSCIENCES, INC. | 2025-04-03 | — | — | US | disclosed |
| US-20250009665-A1 | GASTRO-RESISTANT CONTROLLED RELEASE ORAL DOSAGE FORMS | MINERVA NEUROSCIENCES, INC. | 2025-01-09 | — | — | US | disclosed |
| US-12048768-B2 | Gastro-resistant controlled release oral dosage forms | MINERVA NEUROSCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240016790-A1 | METHODS OF USING A PHENOXYPROPYLAMINE COMPOUND TO TREAT PAIN | PPRS SAS (FR) | 2024-01-18 | — | — | US | disclosed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | disclosed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3925608-A2 | USE OF PHENOXYPROPYLAMINE COMPOUNDS TO TREAT OR IMPROVE AT LEAST ONE DISORDER OR PARAMETER OF SLEEP | Minerva Neurosciences, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| CN-112955145-A | Methods of treating pain using phenoxypropylamine compounds | 密涅瓦神经科学有限公司 | 2021-06-11 | — | — | CN | disclosed |
| EP-2948143-B1 | USE OF PHENOXYPROPYLAMINE COMPOUNDS TO TREAT DEPRESSION | MINERVA NEUROSCIENCES INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200223838-A1 | METHODS OF USE OF PHENOXYPROPYLAMINE COMPOUNDS TO TREAT DEPRESSION | MINERVA NEUROSCIENCES, INC. (US) | 2020-07-16 | — | — | US | disclosed |
| US-20200069672-A1 | METHODS OF USING A PHENOXYPROPYLAMINE COMPOUND TO TREAT PAIN | PPRS SAS (FR) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12048768-B2 | Gastro-resistant controlled release oral dosage forms | CYP2D6, UGT1A3, UGT1A6 | HTR1A 238/4885SLC6A4 26/4885DRD4 1384/4885 |
| US-20250228837-A1 | (2S)-1-[4-(3,4-DICHLOROPHENYL)PIPERIDIN-1-YL]-3-[2-(5-METHYL-1,3,4-OXADIAZOL-2-YL)BENZO[B]FURAN-4-YLOXY] PROPAN-2-OL OR ITS METABOLITE FOR TREATING ANXIETY DISORDERS | HTR2C, HTR1D, HTR2A | HTR1A 9/4885SLC6A4 69/4885DRD4 46/4885 |
| US-20240016790-A1 | METHODS OF USING A PHENOXYPROPYLAMINE COMPOUND TO TREAT PAIN | PNMT, FAP, HNMT | HTR1A 88/4885SLC6A4 7/4885DRD4 2641/4885 |
| US-20200069672-A1 | METHODS OF USING A PHENOXYPROPYLAMINE COMPOUND TO TREAT PAIN | PNMT, FAP, HNMT | HTR1A 88/4885SLC6A4 7/4885DRD4 2641/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | HTR1A 4/4885SLC6A4 30/4885DRD4 981/4885 |
| US-20250109127-A1 | METHODS OF USE OF PHENOXYPROPYLAMINE COMPOUNDS TO TREAT DEPRESSION | HTR5A, HTR7, HTR6 | HTR1A 6/4885SLC6A4 18/4885DRD4 144/4885 |
| US-20250009665-A1 | GASTRO-RESISTANT CONTROLLED RELEASE ORAL DOSAGE FORMS | CYP2D6, UGT1A3, UGT1A6 | HTR1A 238/4885SLC6A4 26/4885DRD4 1384/4885 |
| US-20200223838-A1 | METHODS OF USE OF PHENOXYPROPYLAMINE COMPOUNDS TO TREAT DEPRESSION | HTR5A, HTR7, HTR6 | HTR1A 6/4885SLC6A4 18/4885DRD4 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.